RegisterLogin

Danshensu

CAT: 0804-HY-N1913-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-N1913-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].
CAS Number
[76822-21-4]
Product Name Alternative
Dan shen suan A; Salvianic acid A
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Keap1-Nrf2; NF-κB; Reactive Oxygen Species (ROS) ; SARS-CoV
Type
Natural Products
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Danshensu.html
Purity
98.59
Solubility
DMSO : < 1 mg/mL|H2O : 5 mg/mL (ultrasonic)
Smiles
OC1=C(C=CC(C[C@H](C(O)=O)O)=C1)O
Molecular Formula
C9H10O5
Molecular Weight
198.17
Precautions
H302, H315, H319, H335
References & Citations
[1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43 (4) :771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne) . 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Citation 01
Breast Cancer Res Treat. 2024 Dec;208 (3) :657-671.|Cancer Immunol Immunother. 2025 Jun 30;74 (8) :256.|J Tradit Complement Med. 2025 Feb 7;15 (4) :434-445.|Phytomedicine. 2023 May:113:154743.|Eur J Pharmacol. 2025 Feb 1:177296.

Related Products

CatalogName
HY-122917-01Danshenol A
HY-122963Danshenol B
HY-N3679Danshenol C
HY-N1273715-epi-Danshenol A

Alternative Products

CatalogName
445755-01Danshensu
TN11144-01Danshensu sodium
TB0062Sodium Danshensu
A14779-5Danshensu 5mg
A14779-10Danshensu 10mg
A14779-25Danshensu 25mg

Popular Products